Abbott’s TactiFlex Duo combines pulsed field ablation and radiofrequency energy in one contact-force catheter, giving electrophysiologists a way to move between tissue-selective PFA and conventional thermal ablation without changing platforms during an AFib procedure.
Radiofrequency burns and cryoballoon freezes cardiac tissue to isolate pulmonary veins. Pulsed field ablation instead uses microsecond electrical pulses to disrupt myocardial cells, offering a nonthermal route that may reduce collateral injury while delivering comparable rhythm control.
Johnson & Johnson has received U.S. Food and Drug Administration approval for the Dual Energy Thermocool Smarttouch SF Platform, an integrated cardiac ablation system that allows electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter. The approval places the Johnson & Johnson MedTech electrophysiology business into a more direct U.S. rollout
The Dual Energy THERMOCOOL SMARTTOUCH SF Platform gives electrophysiologists pulsed field and radiofrequency ablation through one catheter, expanding procedural flexibility while raising new questions about evidence, efficiency and adoption.
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.
Johnson & Johnson launches VARIPULSE pulsed field ablation technology in Peru. Discover what this means for atrial fibrillation treatment and electrophysiology innovation.
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The